• BARINDERJIT KAUR
• DR SURYA P GAUTAM

Aim: Evaluation of the cardioprotective activity of ditolylguanidine (DTG), a sigma agonist, on isoproterenol (ISO) induced myocardial infarction in rats. Background: A diverse range of sigma receptor agonists like berberine, fluvoxamine, paroxetine, fluxetine and SA4503 have been reported to possess protective action against myocardial infarction. Therefore, present study mainly designed to investigate the cardioprotective effects of DTG on isoproterenol-induced myocardial infarction in rats. Methodology: Wistar albino rats (n=42) were divided into six groups, control, ISO alone, DTG (10, 15 and 20 mg/kg) plus ISO and DTG (20 mg/kg) plus ISO along with progesterone. ISO (85 mg/kg) was injected subcutaneously for two consecutive days to induce myocardial infarction and progesterone (2 mg/kg) was administered intraperitoneally after 30 min of second dose of ISO. At the end of experiment, rats were sacrificed, blood samples were collected and centrifuged to obtain serum for the LDH and CK estimation and heart tissue was used for myocardial infarct size, tissue weight and histopathological changes. Principle/Findings: Induction of myocardial infarction in rats using ISO results in elevation of infarct size, level of serum marker enzymes (CK-MB, LDH) and histopathological changes. Co-administration with DTG show significant reduction in infarct size and serum marker enzymes (CK-MB, LDH) only at dose high doses (15mg/kg and 20 mg/kg) and prevent heart from histopathological changes but no significant difference was observed on heart/body weight ratio. However, progesterone, a sigma 1 receptor antagonist, did not attenuated the effect of DTG (20 mg/kg) in terms of infarct size, LDH, CK-MB, heart to body weight ratio and histopathological changes during ISO- induced myocardial infarction. Conclusion: DTG, a sigma-1 receptor agonist, attenuated the isoprorerenol induced increase in infarct size, LDH, CK and therefore prevented myocardial injury at high doses, however, this might not be act through σ- receptors.

TO EVALUATE THE THERAPEUTIC POTENTIAL OF DITOLYLGUANIDINE, A SIGMA RECEPTOR AGONIST, IN ISOPROTERENOL INDUCED MYOCARDIAL INJURY IN RAT MODEL

"TO EVALUATE THE THERAPEUTIC POTENTIAL OF DITOLYLGUANIDINE, A SIGMA RECEPTOR AGONIST, IN ISOPROTERENOL INDUCED MYOCARDIAL INJURY IN RAT MODEL", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 5, page no.396-408, May-2019, Available :http://www.jetir.org/papers/JETIR1905W14.pdf

"TO EVALUATE THE THERAPEUTIC POTENTIAL OF DITOLYLGUANIDINE, A SIGMA RECEPTOR AGONIST, IN ISOPROTERENOL INDUCED MYOCARDIAL INJURY IN RAT MODEL", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 5, page no. pp396-408, May-2019, Available at : http://www.jetir.org/papers/JETIR1905W14.pdf